|
Characteristic
|
0–1 RP
|
Grade 2–3 RP
|
P Value
|
|---|
| |
No. of Patients (%)
|
No. of Patients (%)
| |
|---|
|
Sex
| | |
0.882
|
|
Male
|
59 (51.3)
|
8 (53.3)
| |
|
Female
|
56 (48.7)
|
7 (46.7)
| |
|
Age
| | |
0.310
|
|
≥74 years
|
62 (53.9)
|
6 (40.0)
| |
|
<74 years
|
53 (46.1)
|
9 (60.0)
| |
|
COPD stage
| | |
0.154
|
|
0–II
|
62 (53.9)
|
11 (73.3)
| |
|
III–IV
|
53 (46.1)
|
4 (26.7)
| |
|
History of other type of cancer
| | |
0.440
|
|
Yes
|
34 (29.6)
|
3 (20.0)
| |
|
No
|
81 (70.4)
|
12 (80.0)
| |
|
ECOG score before SABR
| | |
0.711
|
|
0–1
|
71 (61.7)
|
10 (66.7)
| |
|
2–3
|
44 (38.3)
|
5 (33.3)
| |
|
Gross tumor volume, cm3
| | |
0.375
|
|
≥9.6
|
55 (47.8)
|
9 (60.0)
| |
|
<9.6
|
60 (52.2)
|
6 (40.0)
| |
|
Planning target volume, cm3
| | |
0.151
|
|
≥73.2
|
54 (47.0)
|
10 (66.7)
| |
|
<73.2
|
61 (53.0)
|
5 (33.3)
| |
|
Tumor location
| | |
0.471
|
|
Peripheral
|
106 (92.2)
|
13 (86.7)
| |
|
Central
|
9 (7.8)
|
2 (13.3)
| |
|
Total lung volume*
|
|
V5
| | |
< 0.001
|
|
≥ 20.2%
|
51 (44.3)
|
14 (93.3)
| |
|
< 20.2%
|
64 (55.7)
|
1 (6.7)
| |
|
V10
| | |
< 0.001
|
|
≥ 14.3%
|
51 (44.3)
|
14 (93.3)
| |
|
< 14.3%
|
64 (55.7)
|
1 (6.7)
| |
|
V15
| | |
0.003
|
|
≥ 11.0%
|
52 (45.2)
|
13 (86.7)
| |
|
< 11.0%
|
63 (54.8)
|
2 (13.3)
| |
|
V20
| |
0.055
| |
|
≥ 8.5%
|
54 (47.0)
|
11 (73.3)
| |
|
< 8.5%
|
61 (53.0)
|
4 (26.7)
| |
|
V25
| | |
0.055
|
|
≥ 6.4%
|
54 (47.0)
|
11 (73.3)
| |
|
< 6.4%
|
61 (53.0)
|
4 (26.7)
| |
|
V30
| | |
0.003
|
|
≥ 5.0%
|
52 (45.2)
|
13 (86.7)
| |
|
< 5.0%
|
63 (54.8)
|
2 (13.3)
| |
|
V35
| | |
0.003
|
|
≥ 3.9%
|
52 (45.2)
|
13 (86.7)
| |
|
< 3.9%
|
63 (54.8)
|
2 (13.3)
| |
|
V40
| | |
0.013
|
|
≥ 3.1%
|
53 (46.1)
|
12 (80.0)
| |
|
< 3.1%
|
62 (53.9)
|
3 (20.0)
| |
|
Mean dose to total lung volume
| | |
0.013
|
|
≥ 5.05 Gy
|
53 (46.1)
|
12 (80.0)
| |
|
< 5.05 Gy
|
62 (53.9)
|
3 (20.0)
| |
|
Ipsilateral lung volume†
|
|
V5
| | |
< 0.001
|
|
≥ 37.7%
|
51 (44.3)
|
14 (93.3)
| |
|
< 37.7%
|
64 (55.7)
|
1 (6.7)
| |
|
V10
| | |
< 0.001
|
|
≥ 28.5%
|
51 (44.3)
|
14 (93.3)
| |
|
< 28.5%
|
64 (55.7)
|
1 (6.7)
| |
|
V15
| | |
< 0.001
|
|
≥ 21.9%
|
51 (44.3)
|
14 (93.3)
| |
|
< 21.9%
|
64 (55.7)
|
1 (6.7)
| |
|
V20
| | |
< 0.001
|
|
≥ 16.9%
|
51 (44.3)
|
14 (93.3)
| |
|
< 16.9%
|
64 (55.7)
|
1 (6.7)
| |
|
V25
| | |
0.003
|
|
≥ 13.1%
|
52 (45.2)
|
13 (86.7)
| |
|
< 13.1%
|
63 (54.8)
|
2 (13.3)
| |
|
V30
| | |
0.013
|
|
≥ 10.4%
|
53 (46.1)
|
12 (80.0)
| |
|
< 10.4%
|
62 (53.9)
|
3 (20.0)
| |
|
V35
| | |
0.003
|
|
≥ 8.1%
|
52 (45.2)
|
13 (86.7)
| |
|
< 8.1%
|
63 (54.8)
|
2 (13.3)
| |
|
V40
| | |
0.013
|
|
≥ 6.3%
|
53 (46.1)
|
12 (80.0)
| |
|
< 6.3%
|
62 (53.9)
|
3 (20.0)
| |
|
Mean dose to ipsilateral lung volume
| | |
< 0.001
|
|
≥9.14 Gy
|
51 (44.3)
|
14 (93.3)
| |
|
<9.14 Gy
|
64 (55.7)
|
1 (6.7)
| |
- * Defined as right plus left lungs minus the gross tumor volume.
- † Defined as the lung containing the lesion to be treated, minus the gross tumor volume.
- Abbreviations: RP, radiation pneumonitis; COPD, chronic obstructive pulmonary disease; ECOG, Eastern Cooperative Oncology Group; SABR, stereotactic ablative radiotherapy; Vx, volume of lung receiving =x Gy; GTV, gross tumor volume; MLD, mean lung dose.
